Drug Development
Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed execs for more details; Merck and Roche also released Q4 and full year earnings, with Eli Lilly, Novo Nordisk and others reporting Wednesday; REGENXBIO hits a regulatory snag ahead of its upcoming PDUFA; more.
FEATURED STORIES
AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.
With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The clinical trial, which will be conducted by Xilio, will assess XTX101’s safety and efficacy as a monotherapy, as well as in combination with Keytruda, in solid tumors.
The White House has also called for an independent investigation and more information from China about the pandemic’s origins.
AbbVie is aiming Skyrizi and Rinvoq at various indications to augment expected declines in the use of its $20-billion-generating-powerhouse Humira, which will lose patent protection in 2023.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 25, 2021.
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
The Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a new compound that blocks the life cycle of the mosquito-borne parasite that causes malaria.
The disclosure comes the day before the WHO is expected to plan for the next phase of investigations into the origins of COVID-19.
Takeda has touted the potential of its Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
NGM Bio’s aldafermin failed to hit its primary endpoint in its Phase IIB trial because of that, the company decides to shift resources to other programs.
If approved, Takeda said Maribavir would become the first and only treatment indicated for CMV infection in refractory patients.